KLOW is a healing & repair research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
KLOW is a pre-mixed lyophilized research formulation containing four compounds: TB-500 (Thymosin Beta-4 synthetic analogue), BPC-157 (Body Protection Compound-157), KPV (Lys-Pro-Val tripeptide), and GHK-Cu (copper peptide). KLOW extends the GLOW formulation (TB-500 + BPC-157 + GHK-Cu) by incorporating KPV, an anti-inflammatory tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH). KPV adds a fourth mechanistic layer: direct suppression of NF-κB nuclear translocation and inflammatory cytokine production, particularly relevant in research models where chronic or excessive inflammation is a co-pathology alongside impaired tissue regeneration. The combination targets dermal, mucosal, and connective tissue repair research with a concurrent anti-inflammatory dimension.
The scientific basis for adding KPV to the GLOW triplex is KPV's established anti-inflammatory activity in intestinal epithelial and macrophage models, its preservation of epithelial tight junctions under inflammatory challenge, and its documented efficacy in murine colitis models. In dermal research contexts, inflammation is a critical regulator of wound healing quality — excessive NF-κB-driven inflammation promotes scarring (hypertrophic scar, keloid) while inadequate inflammation impairs innate immune debridement. KPV's selective NF-κB suppression, combined with TB-500's actin-dependent migration, BPC-157's angiogenic signalling, and GHK-Cu's ECM remodelling activity, creates a four-pathway approach to tissue repair modelling that spans the full healing cascade.
PeptidesFromChina.co supplies KLOW as lyophilized powder in sealed vials. Each component is individually purity-verified by HPLC before blending. Certificates of Analysis available per batch. Wholesale quantities on request. For laboratory research use only.
| Formulation Type | Pre-mixed Lyophilized Research Blend (4 components) |
|---|---|
| Component 1 | TB-500 (Thymosin Beta-4 fragment) |
| Component 2 | BPC-157 (Body Protection Compound-157) |
| Component 3 | KPV (Lys-Pro-Val — α-MSH C-terminal tripeptide) |
| Component 4 | GHK-Cu (Glycyl-L-histidyl-L-lysine : Cu²⁺) |
| KPV Mechanism | NF-κB suppression, epithelial barrier protection, IL-1β/TNF-α reduction |
| Research Category | Skin & Hair, Tissue Repair, Inflammatory Wound Models, GI Mucosal |
| Vs. GLOW | KLOW = GLOW + KPV (additional anti-inflammatory component) |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 14 days) |
| CAS Number | N/A — combination product |
| Molecular Weight | N/A — see individual component COAs |
| Molecular Formula | N/A — combination product |
| Sequence | N/A — combination product |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| KLOW | 80 mg | 10 vials | ≥98% | In Stock | $244.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Chronic wounds (diabetic ulcers, pressure injuries) and hypertrophic scarring are characterised by dysregulated inflammatory signalling — excessive and prolonged NF-κB-driven cytokine production that prevents transition from the inflammatory to the proliferative phase of repair. KPV's NF-κB suppression, characterised in macrophage (RAW264.7, THP-1) and intestinal epithelial (Caco-2, HT-29) cell line models, is the mechanistic target in these research designs. In KLOW combination studies, KPV's anti-inflammatory activity is assessed alongside BPC-157's angiogenic effect and GHK-Cu's collagen output using multiplexed endpoints — cytokine secretion (Luminex), wound closure (scratch assay), and ECM deposition (Sircol, Sirius Red staining).
KPV is among the most studied α-MSH-derived tripeptides in GI research, with documented activity in TNBS-induced colitis, DSS colitis, and LPS-challenged intestinal epithelial models. KPV reduces IL-8, TNF-α, and IL-6 secretion from inflamed epithelial cells while preserving tight junction protein expression (ZO-1, occludin, claudin-1) in barrier integrity assays (TEER). In KLOW formulations studied in GI contexts, BPC-157's established gastroprotective and cytoprotective activity in the GI tract (ulcer, anastomosis, and fistula models) complements KPV's anti-inflammatory epithelial activity — providing both direct mucosal repair and inflammatory suppression simultaneously.
Inflammatory skin conditions (atopic dermatitis, psoriasis, rosacea) involve keratinocyte NF-κB activation, mast cell degranulation, and dysregulated cytokine networks alongside impaired barrier function. KPV's MC1R-independent anti-inflammatory activity in keratinocytes (at concentrations of 1–100 nM) is studied alongside GHK-Cu's barrier-restoring collagen and elastin stimulation in reconstructed human epidermis models and in vivo oxazolone-induced contact hypersensitivity models in mice. Histological endpoints (epidermal thickness, mast cell density, CD11b+ infiltrate) are complemented by cytokine profiling of dermal extracts.
A specific research application for KLOW is the study of combination pharmacology — whether four mechanistically distinct compounds produce additive or synergistic effects when applied simultaneously. Full factorial dose-response designs (varying each component independently and in combination) are used in multi-well plate formats to generate interaction surface data. Bliss independence and Loewe additivity models are applied to quantify whether combination effects exceed the predicted additive outcome. These studies inform whether fixed-ratio blends (as in KLOW) are pharmacologically advantageous over individual compound administration at equivalent total doses.
GLOW contains TB-500, BPC-157, and GHK-Cu — targeting tissue repair via cell migration, angiogenesis, and ECM remodelling. KLOW adds KPV (Lys-Pro-Val), an α-MSH-derived anti-inflammatory tripeptide that suppresses NF-κB and reduces inflammatory cytokine production. KLOW is selected for research models where inflammation is a significant co-pathology: chronic wounds, inflammatory bowel disease, atopic dermatitis, or any repair model where excessive inflammation impairs the proliferative phase of healing.
NF-κB suppression by KPV is measured using: (1) NF-κB luciferase reporter assays in TNF-α or LPS-stimulated HEK293 or RAW264.7 cells; (2) nuclear p65 translocation by immunofluorescence or subcellular fractionation/Western blot; (3) downstream cytokine secretion (IL-6, TNF-α, IL-1β by ELISA or Luminex). These assays confirm that KPV at 1–100 nM produces significant NF-κB pathway suppression without cytotoxicity, and that it acts upstream of IκB kinase rather than directly at the NF-κB DNA binding site.
Yes. Each component has a distinct molecular weight and chromatographic retention time, allowing RP-HPLC analysis to resolve and quantify all four simultaneously in a single run. ESI-MS confirms identity of each component. If researchers need individual component concentrations post-reconstitution for assay calculations, analytical characterisation using reverse-phase HPLC with UV detection at 214 nm provides clear resolution of BPC-157, TB-500, KPV, and GHK-Cu peaks.
Yes. KLOW is available through PeptidesFromChina.co on a B2B wholesale basis. Contact us via the Request page for pricing, minimum order quantities, and volume tier information after account verification.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.